Breaking News


Topical INCB-018424 displays safety and efficacy in patients with psoriasis


The safety, tolerability and efficacy of topical application of INCB-018424 in the treatment of psoriasis were evaluated in two recent studies. INCB-018424 is a preferential inhibitor of Janus kinase (JAK) 1 and 2, which are implicated in the pathogenesis of psoriasis by mediating signal transduction cascades of cytokines. Patients with active, stable plaque psoriasis participated in the two 28-day studies. In the first study, a double-blind assessment of INCB-018424 versus active comparators and vehicle control was performed. The study revealed reductions in mean lesion scores by 53% using 1% INCB-018424 cream q.d. and 54% with 1.5% INCB-018424 cream b.i.d. compared to vehicle controls (32 and 27% reduction, respectively). The reduction in ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list